Lippincott Journals Subscribers, use your username or email along with your password to log in.
Registered users can save articles, searches, and manage email alerts.
All registration fields are required.
Flash Player 9.0.0 is required for the Video Gallery.
Get Adobe Flash Player.
Friend's E-mail is Invalid
Your message has been successfully sent to your friend.
February 10th, 2014, Volume 36, Issue 3;
Richard Furman, MD, discusses the Phase III trial of idelalisib, a first-in-class oral kinase inhibitor and highly selective inhibitor of the delta isoform of PI3 kinase, used in combination with rituximab. The data show better progression-free survival and objective response rates compared with rituximab plus placebo in CLL patients who had already received standard treatments and were not considered candidates for additional chemotherapy.